Compare CALM & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALM | DNLI |
|---|---|---|
| Founded | 1957 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 1996 | 2017 |
| Metric | CALM | DNLI |
|---|---|---|
| Price | $61.19 | $19.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 20 |
| Target Price | ★ $68.33 | $35.50 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 09-30-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,911,632,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.37 | $157.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $60.13 | $13.75 |
| 52 Week High | $95.25 | $27.30 |
| Indicator | CALM | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 33.81 | 45.98 |
| Support Level | $61.01 | $17.75 |
| Resistance Level | $80.00 | $19.35 |
| Average True Range (ATR) | 1.88 | 0.77 |
| MACD | 0.36 | 0.19 |
| Stochastic Oscillator | 17.40 | 71.62 |
Cal-Maine Foods Inc is an egg company in the U.S. Its shell egg portfolio includes conventional, specialty, cage-free, nutritionally enhanced, organic, brown, pasture-raised, and free-range eggs. The Company operates through the Conventional Shell Eggs, Specialty Shell Eggs and Prepared Foods segments, with Conventional Shell Eggs generating maximum revenue. The Conventional Shell Eggs segment consists mainly of the production, grading, packaging, marketing and distribution of conventional shell eggs, including Sunups and Sunny Meadow. The Company sells its products to grocery store chains, club stores, independent supermarkets, and foodservice distributors serving restaurants, convenience stores, healthcare and education facilities, and hotels throughout the U.S.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.